A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018-- Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug Designation by the United States Food and... read more →
South San Francisco, California – September 26, 2018. Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform,... read more →
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief... read more →
Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and TheLeukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s... read more →
Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with... read more →
SutroVax Announces $85M Series C Financing led by TPG Growth
https://califesciences.org/california-life-sciences-association-elects-new-board-chair-adds-new-board-member/
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate,... read more →
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate... read more →
Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American... read more →